Vaxart (VXRT) CFO granted 227,000 shares and 455,000 options in Form 4

Rhea-AI Filing Summary

Vaxart, Inc.’s Chief Financial Officer, Jeroen Nicolaas Grasman, reported equity compensation grants. He was awarded 227,000 shares of Common Stock upon vesting of restricted stock units, bringing his direct Common Stock holdings to 577,000 shares.

He also received a stock option covering 455,000 shares of Common Stock at an exercise price of $0.6795 per share, expiring on March 16, 2036. The restricted stock units vest 25% on March 16, 2026 and then annually so they are fully vested on the fourth anniversary, while the option vests 25% on March 16, 2027 and then in 36 equal monthly installments until fully vested on March 16, 2030. These are compensation-related awards rather than open-market purchases.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Grasman Jeroen Nicolaas

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	455,000	$0.00	--
Grant/Award	Common Stock	227,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 455,000 shares (Direct); Common Stock — 577,000 shares (Direct)

Footnotes (1)

1. Grant of shares upon vesting of restricted stock units. 25% of the shares underlying the award shall vest on each anniversary of the vesting commencement date of March 16, 2026, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 16, 2027, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 16, 2030.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grasman Jeroen Nicolaas

(Last) (First) (Middle)

C/O VAXART, INC.

170 HARBOR WAY, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxart, Inc. [ VXRT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		A		227,000(1)	A	$0	577,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.6795	03/16/2026		A		455,000		(2)	03/16/2036	Common Stock	455,000	$0	455,000	D

Explanation of Responses:

1. Grant of shares upon vesting of restricted stock units. 25% of the shares underlying the award shall vest on each anniversary of the vesting commencement date of March 16, 2026, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date.

2. The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 16, 2027, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 16, 2030.

	/s/ Edward B. Berg	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Vaxart (VXRT) disclose about its CFO’s recent Form 4 transactions?

Vaxart reported that CFO Jeroen Nicolaas Grasman received equity compensation on March 16, 2026, including restricted stock units and a stock option grant. These awards increase his share and option holdings but do not involve any open-market stock purchases or sales.

How many Vaxart (VXRT) shares did the CFO receive in this Form 4 filing?

The CFO was granted 227,000 shares of Vaxart Common Stock through vesting of restricted stock units. After this grant, his direct Common Stock ownership totals 577,000 shares, reflecting compensation-based awards rather than market transactions or discretionary share purchases.

What stock option grant did the Vaxart (VXRT) CFO receive and at what price?

The CFO received a stock option for 455,000 shares of Vaxart Common Stock with an exercise price of $0.6795 per share. The option expires on March 16, 2036 and represents long-term incentive compensation, not an immediate stock purchase.

What is the vesting schedule for the Vaxart (VXRT) CFO’s restricted stock units?

The restricted stock units vest over four years starting March 16, 2026. Twenty-five percent of the underlying shares vest on each anniversary of that date, so the award becomes fully vested on the fourth anniversary, aligning compensation with multi-year service and performance.

How do the Vaxart (VXRT) CFO’s new stock options vest over time?

The stock options vest 25% on March 16, 2027, the first anniversary of vesting commencement, then in 36 equal monthly installments. This structure leads to full vesting by March 16, 2030, encouraging long-term alignment between the CFO and shareholder interests.

Did the Vaxart (VXRT) CFO buy or sell shares on the open market in this Form 4?

No open-market buys or sells were reported. The Form 4 shows acquisitions classified as grants and awards: restricted stock units converting into shares and a new stock option grant. Net buy-sell activity is neutral, reflecting compensation rather than trading decisions.